Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Prevalence and incidence of thyroid dysfunction in type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of adults: The Fremantle Diabetes Study Phase II.

Peters KE, Chubb SAP, Bruce DG, Davis WA, Davis TME.

Clin Endocrinol (Oxf). 2020 Jan 27. doi: 10.1111/cen.14164. [Epub ahead of print]

PMID:
31984536
2.

A comparison of obesity indices in relation to mortality in type 2 diabetes: the Fremantle Diabetes Study.

Tate J, Knuiman M, Davis WA, Davis TME, Bruce DG.

Diabetologia. 2020 Mar;63(3):528-536. doi: 10.1007/s00125-019-05057-8. Epub 2019 Dec 14.

PMID:
31838571
3.

Response to Comment on Davis et al. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: the Fremantle Diabetes Study Phase I. Diabetes Care 2018;42:102-109.

Davis WA, Hamilton EJ, Bruce DG, Davis TME.

Diabetes Care. 2019 Jun;42(6):e101. doi: 10.2337/dci19-0015. No abstract available.

PMID:
31110125
4.

Subjective memory complaints are not increased in type 2 diabetes: A matched cohort study.

Bruce DG, Davis WA, Hunter ML, Davis TME.

J Diabetes Complications. 2019 Jun;33(6):424-426. doi: 10.1016/j.jdiacomp.2019.04.001. Epub 2019 Apr 7.

PMID:
31054798
5.

Dementia complicating type 2 diabetes and the influence of premature mortality: the Fremantle Diabetes Study.

Bruce DG, Davis TME, Davis WA.

Acta Diabetol. 2019 Jul;56(7):767-776. doi: 10.1007/s00592-019-01322-9. Epub 2019 Apr 3.

PMID:
30945048
6.

Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.

Drinkwater JJ, Davis TME, Turner AW, Bruce DG, Davis WA.

Diabetes Care. 2019 Feb;42(2):288-296. doi: 10.2337/dc18-1556. Epub 2018 Dec 6.

PMID:
30523034
7.

Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I.

Davis WA, Hamilton EJ, Bruce DG, Davis TME.

Diabetes Care. 2019 Jan;42(1):102-109. doi: 10.2337/dc18-1486. Epub 2018 Nov 19.

PMID:
30455327
8.

Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study.

Davis TME, Bruce DG, Finn J, Curtis BH, Barraclough H, Davis WA.

Diabetes Obes Metab. 2019 Mar;21(3):648-657. doi: 10.1111/dom.13568. Epub 2018 Nov 25.

PMID:
30370611
9.

Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.

Bruce DG, Davis WA, Davis TME.

Diabetes Obes Metab. 2018 Dec;20(12):2852-2859. doi: 10.1111/dom.13469. Epub 2018 Aug 10.

10.

The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study.

Peters KE, Davis WA, Beilby J, Hung J, Bruce DG, Davis TME.

Diabetes Res Clin Pract. 2018 Sep;143:62-70. doi: 10.1016/j.diabres.2018.06.005. Epub 2018 Jun 30.

PMID:
29969725
11.

The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II.

Davis TME, Bruce DG, Curtis BH, Barraclough H, Davis WA.

Diabetes Res Clin Pract. 2018 Aug;142:294-302. doi: 10.1016/j.diabres.2018.05.047. Epub 2018 Jun 4.

PMID:
29879496
12.

Clinical risk factors for depressive syndrome in Type 2 diabetes: the Fremantle Diabetes Study.

Bruce DG, Davis WA, Starkstein SE, Davis TME.

Diabet Med. 2018 Jul;35(7):903-910. doi: 10.1111/dme.13631. Epub 2018 May 2.

PMID:
29608787
13.

Hippocampal atrophy, asymmetry, and cognition in type 2 diabetes mellitus.

Milne NT, Bucks RS, Davis WA, Davis TME, Pierson R, Starkstein SE, Bruce DG.

Brain Behav. 2017 Dec 22;8(1):e00741. doi: 10.1002/brb3.741. eCollection 2018 Jan.

14.

The utility of the Diabetes Anxiety Depression Scale in Type 2 diabetes mellitus: The Fremantle Diabetes Study Phase II.

Davis WA, Bruce DG, Dragovic M, Davis TME, Starkstein SE.

PLoS One. 2018 Mar 15;13(3):e0194417. doi: 10.1371/journal.pone.0194417. eCollection 2018.

15.

Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase II.

Davis WA, Peters KE, Makepeace A, Griffiths S, Bundell C, Grant SFA, Ellard S, Hattersley AT, Paul Chubb SA, Bruce DG, Davis TME.

Intern Med J. 2018 Jul;48(7):803-809. doi: 10.1111/imj.13792.

16.

Risk and associates of incident hip fracture in type 1 diabetes: The Fremantle Diabetes Study.

Hamilton EJ, Davis WA, Bruce DG, Davis TME.

Diabetes Res Clin Pract. 2017 Dec;134:153-160. doi: 10.1016/j.diabres.2017.10.011. Epub 2017 Oct 18.

PMID:
29054483
17.

Depression symptoms are persistent in Type 2 diabetes: risk factors and outcomes of 5-year depression trajectories using latent class growth analysis.

Whitworth SR, Bruce DG, Starkstein SE, Davis WA, Davis TME, Skinner TC, Bucks RS.

Diabet Med. 2017 Aug;34(8):1108-1115. doi: 10.1111/dme.13372. Epub 2017 May 16.

PMID:
28453875
18.

Anemia complicating type 2 diabetes: Prevalence, risk factors and prognosis.

Gauci R, Hunter M, Bruce DG, Davis WA, Davis TME.

J Diabetes Complications. 2017 Jul;31(7):1169-1174. doi: 10.1016/j.jdiacomp.2017.04.002. Epub 2017 Apr 6.

PMID:
28433448
19.

Epidemiological Approaches to Understanding the Link Between Type 2 Diabetes and Dementia.

Sutherland GT, Lim J, Srikanth V, Bruce DG.

J Alzheimers Dis. 2017;59(2):393-403. doi: 10.3233/JAD-161194. Review.

PMID:
28372332
20.

Low serum HDL-cholesterol concentrations in mid-life predict late-life cognitive impairment in type 2 diabetes: The Fremantle diabetes study.

Bruce DG, Davis WA, Davis TME.

J Diabetes Complications. 2017 Jun;31(6):945-947. doi: 10.1016/j.jdiacomp.2016.12.009. Epub 2017 Jan 20.

PMID:
28258907
21.

The Structured Interview for Insight and Judgment in Dementia: Development and validation of a new instrument to assess awareness in patients with dementia.

Parrao T, Brockman S, Bucks RS, Bruce DG, Davis WA, Hatch KK, Leavy TL, Axten CA, Starkstein SE.

Alzheimers Dement (Amst). 2016 Dec 26;7:24-32. doi: 10.1016/j.dadm.2016.12.012. eCollection 2017.

22.

Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study.

Peters KE, Davis WA, Taddei K, Martins RN, Masters CL, Davis TM, Bruce DG.

J Alzheimers Dis. 2017;56(3):1127-1133. doi: 10.3233/JAD-161050.

PMID:
28106562
23.

Influence of Premature Mortality on the Link Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study.

Hamilton E, Davis WA, Bruce DG, Davis TM.

J Clin Endocrinol Metab. 2017 Feb 1;102(2):551-559. doi: 10.1210/jc.2016-3570.

24.

Lifetime depression and anxiety increase prevalent psychological symptoms and worsen glycemic control in type 2 diabetes: The Fremantle Diabetes Study Phase II.

Whitworth SR, Bruce DG, Starkstein SE, Davis WA, Davis TM, Bucks RS.

Diabetes Res Clin Pract. 2016 Dec;122:190-197. doi: 10.1016/j.diabres.2016.10.023. Epub 2016 Nov 9.

PMID:
27865961
25.

Dementia onset, incidence and risk in type 2 diabetes: a matched cohort study with the Fremantle Diabetes Study Phase I.

Davis WA, Zilkens RR, Starkstein SE, Davis TM, Bruce DG.

Diabetologia. 2017 Jan;60(1):89-97. Epub 2016 Oct 7.

26.

Comorbid Anxiety and Depression and Their Impact on Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.

Bruce DG, Davis WA, Dragovic M, Davis TM, Starkstein SE.

Depress Anxiety. 2016 Oct;33(10):960-966. doi: 10.1002/da.22523. Epub 2016 May 10.

PMID:
27164424
27.

Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study.

Davis TM, Chubb SA, Bruce DG, Davis WA.

Diabetes Obes Metab. 2016 Jun;18(6):598-606. doi: 10.1111/dom.12655. Epub 2016 Apr 12.

PMID:
26936654
28.

A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy.

Starkstein SE, Brockman S, Hatch KK, Bruce DG, Almeida OP, Davis WA, Robinson RG.

J Stroke Cerebrovasc Dis. 2016 May;25(5):1119-1127. doi: 10.1016/j.jstrokecerebrovasdis.2016.01.032. Epub 2016 Feb 22.

PMID:
26915605
29.

Lifetime depression history and depression risk in type 2 diabetes: A case-control study.

Bruce DG, Davis WA, Hunter ML, Peters KE, Davis TM, Starkstein SE.

J Diabetes Complications. 2016 Jan-Feb;30(1):38-42. doi: 10.1016/j.jdiacomp.2015.10.010. Epub 2015 Oct 21.

PMID:
26604164
30.

The interactive effects of type 2 diabetes mellitus and schizophrenia on all-cause mortality: The Fremantle Diabetes Study.

Davis WA, Starkstein SE, Bruce DG, Davis TM.

J Diabetes Complications. 2015 Nov-Dec;29(8):1320-2. doi: 10.1016/j.jdiacomp.2015.08.019. Epub 2015 Aug 28.

PMID:
26387807
31.

Type 2 diabetes mellitus and biomarkers of neurodegeneration.

Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurology. 2015 Sep 29;85(13):1123-30. doi: 10.1212/WNL.0000000000001982. Epub 2015 Sep 2.

32.

Risk of suicide in Australian adults with diabetes: the Fremantle Diabetes Study.

Davis WA, Starkstein SE, Bruce DG, Davis TM.

Intern Med J. 2015 Sep;45(9):976-80. doi: 10.1111/imj.12853.

PMID:
26332624
33.

Type 2 diabetes and cognitive function: many questions, few answers.

Bruce DG.

Lancet Neurol. 2015 Mar;14(3):241-2. doi: 10.1016/S1474-4422(14)70299-6. Epub 2015 Feb 16. No abstract available.

PMID:
25728433
34.

Prevalence of depression and its associations with cardio-metabolic control in Aboriginal and Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study Phase II.

Davis TM, Hunt K, Bruce DG, Starkstein S, Skinner T, McAullay D, Davis WA.

Diabetes Res Clin Pract. 2015 Mar;107(3):384-91. doi: 10.1016/j.diabres.2014.12.014. Epub 2015 Jan 21.

PMID:
25656760
35.

Apathy in older patients with type 2 diabetes.

Bruce DG, Nelson ME, Mace JL, Davis WA, Davis TM, Starkstein SE.

Am J Geriatr Psychiatry. 2015 Jun;23(6):615-21. doi: 10.1016/j.jagp.2014.09.010. Epub 2014 Oct 2.

36.

Diagnostic criteria for depression in type 2 diabetes: a data-driven approach.

Starkstein SE, Davis WA, Dragovic M, Cetrullo V, Davis TM, Bruce DG.

PLoS One. 2014 Nov 12;9(11):e112049. doi: 10.1371/journal.pone.0112049. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122324.

37.
38.

Mid-life predictors of cognitive impairment and dementia in type 2 diabetes mellitus: the Fremantle Diabetes Study.

Bruce DG, Davis WA, Starkstein SE, Davis TM.

J Alzheimers Dis. 2014;42 Suppl 3:S63-70. doi: 10.3233/JAD-132654.

PMID:
24840567
39.

Clinical impact of the temporal relationship between depression and type 2 diabetes: the Fremantle diabetes study phase II.

Bruce DG, Davis WA, Cetrullo V, Starkstein SE, Davis TM.

PLoS One. 2013 Dec 4;8(12):e81254. doi: 10.1371/journal.pone.0081254. eCollection 2013.

40.

Personality traits, self-care behaviours and glycaemic control in type 2 diabetes: the Fremantle diabetes study phase II.

Skinner TC, Bruce DG, Davis TM, Davis WA.

Diabet Med. 2014 Apr;31(4):487-92. doi: 10.1111/dme.12339. Epub 2013 Nov 18.

PMID:
24147848
41.

Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010.

Zilkens RR, Duke J, Horner B, Semmens JB, Bruce DG.

Alzheimers Dement. 2014 May;10(3):310-8. doi: 10.1016/j.jalz.2013.04.001. Epub 2013 Jul 10.

PMID:
23849590
42.

Earlier age of dementia onset and shorter survival times in dementia patients with diabetes.

Zilkens RR, Davis WA, Spilsbury K, Semmens JB, Bruce DG.

Am J Epidemiol. 2013 Jun 1;177(11):1246-54. doi: 10.1093/aje/kws387. Epub 2013 Mar 28.

PMID:
23543134
43.

A comprehensive investigation of variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/R2), and their association with serum adiponectin, type 2 diabetes, insulin resistance and the metabolic syndrome.

Peters KE, Beilby J, Cadby G, Warrington NM, Bruce DG, Davis WA, Davis TM, Wiltshire S, Knuiman M, McQuillan BM, Palmer LJ, Thompson PL, Hung J.

BMC Med Genet. 2013 Jan 25;14:15. doi: 10.1186/1471-2350-14-15.

44.

Antenatal monitoring of anti-D and anti-c: could titre scores determined by column agglutination technology replace continuous flow analyser quantification?

Bruce DG, Tinegate HN, Williams M, Babb R, Wells AW.

Transfus Med. 2013 Feb;23(1):36-41. doi: 10.1111/tme.12002. Epub 2012 Nov 28.

PMID:
23339459
45.

Determinants and costs of community nursing in patients with type 2 diabetes from a community-based observational study: the Fremantle Diabetes Study.

Davis WA, Lewin G, Davis TM, Bruce DG.

Int J Nurs Stud. 2013 Sep;50(9):1166-71. doi: 10.1016/j.ijnurstu.2012.11.013. Epub 2012 Dec 14.

PMID:
23245706
46.

Long-term mortality risks associated with mild anaemia in older persons: the Busselton Health Study.

Chalmers KA, Knuiman MW, Divitini ML, Bruce DG, Olynyk JK, Milward EA.

Age Ageing. 2012 Nov;41(6):759-64. doi: 10.1093/ageing/afs150. Epub 2012 Sep 27.

PMID:
23019140
47.

Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study.

Magliano DJ, Davis WA, Shaw JE, Bruce DG, Davis TM.

Eur J Endocrinol. 2012 Oct;167(4):589-99. doi: 10.1530/EJE-12-0053. Epub 2012 Aug 14.

48.

Continuing disparities in cardiovascular risk factors and complications between aboriginal and Anglo-Celt Australians with type 2 diabetes: the Fremantle Diabetes Study.

Davis TM, Hunt K, McAullay D, Chubb SA, Sillars BA, Bruce DG, Davis WA.

Diabetes Care. 2012 Oct;35(10):2005-11. Epub 2012 Jul 18.

49.

Cohort profile: the Fremantle Diabetes Study.

Davis TM, Bruce DG, Davis WA.

Int J Epidemiol. 2013 Apr;42(2):412-21. doi: 10.1093/ije/dys065. Epub 2012 Apr 28. No abstract available.

PMID:
22544845
50.

Prevalence, incidence, and prognosis of hepatobiliary disease in community-based patients with type 2 diabetes: the Fremantle Diabetes Study.

Davis TM, Peters KE, Bruce DG, Davis WA.

J Clin Endocrinol Metab. 2012 May;97(5):1581-8. doi: 10.1210/jc.2011-3232. Epub 2012 Feb 22.

PMID:
22362822

Supplemental Content

Loading ...
Support Center